Stockreport

Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update

Compass Therapeutics, Inc.  (CMPX) 
PDF Completed enrollment of the 150 patients in the COMPANION-002 Study, a Phase 2/3 trial of CTX-009 (DLL4 and VEGF-A bispecific antibody) plus paclitaxel versus paclitaxel [Read more]